Abstract
The World Health Organization has urged to set up artemisinin-based combination therapy (artemisinin and effective antimalarial drug) and gradually pull out oral artemisinin mono-therapies from the making of prescription due to their high recrudescence rates and to reduce the risk of drug resistance. Prescription practices by physicians and the availability of oral artemisinin monotherapies with pharmacists directly affect the pattern of their use as a result the first clinical case report of only artesunate resistant P. falciparum malaria has been found from Kolkata. A significant failure rate of artesunate and SP (9.5%) has recently been observed in the district Jalpaiguri, West Bengal, though no specific mutation has been observed in pfATPase6 gene. In view of the above findings to get a clear picture of artemisinin resistance in P. falciparum a thorough study is required involving in vivo, in vitro and molecular procedures in this vulnerable area.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
